"A world-wide prospective study of INC on prognosis and biomarkers in GBS"

A world-wide prospective study of INC on prognosis and biomarkers in GBS

2000 inclusions!

Patient 2000 was inclused on May5th by Dr. Gerardo Gutierrez Gutierrez!

What are the implications of reaching this IGOS-2000 milestone?

  1. From now on it will not be possible to include new patients in IGOS; the website is now closed for new inclusions.
  2. It is important to continue the collection of follow-up data and samples from previously included patients. This collection will continue until the last (3 year) follow-up visit of the last included patients (so May 2024). During that window the website will be open for collecting these follow-up data.
  3. We are about to start a new round of data quality assessments for the first 2000 patients included in IGOS. You will all be approached for this in the coming months.
  4. We will also plan new transports of materials to Erasmus MC.
More >>

PNS virtual meeting 2020

During the first virtual PNS Annual Meeting, the IGOS Meeting was also held online for the first time. We celebrate a succesful meeting but hope the next PNS meeting will be held in person in the beautiful Copenhagen.More >>
More news

Publications

  1. Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré Syndrome : https://pubmed.ncbi.nlm.nih.gov/28406555/
  2. Regional variation of Guillain-Barré syndrome: https://doi.org/10.1093/brain/awy232
  3. Guillain–Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity: https://doi.org/10.1007/s00415-018-9151-x
  4. Current treatment practice of Guillain-Barré syndrome: https://n.neurology.org/content/93/1/e59.long
  5. Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study : https://jnnp.bmj.com/content/91/2/113
  6. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study : https://jnnp.bmj.com/content/92/10/1080.long
  7. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study: https://pubmed.ncbi.nlm.nih.gov/34553216/
  8. Antecedent infections in Guillain-Barré syndrome in endemic areas of arbovirus transmission: A multinational case-control study, https://pubmed.ncbi.nlm.nih.gov/34549484/
  9. Predicting Outcome in Guillain-Barré Syndrome: https://n.neurology.org/content/98/5/e518.long
  10. International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score: https://pubmed.ncbi.nlm.nih.gov/35106830/
  11. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values: https://pubmed.ncbi.nlm.nih.gov/35078730/
  12. Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh, https://pubmed.ncbi.nlm.nih.gov/35908170/
  13. Electrodiagnostic subtyping in Guillain-Barré syndrome: use of criteria in practice based on a survey study in IGOS: https://pubmed.ncbi.nlm.nih.gov/35700346/
  14. An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS 1000-Cohort: https://pubmed.ncbi.nlm.nih.gov/35981895/
  15. Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome https://pubmed.ncbi.nlm.nih.gov/36428088/
  16. Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome: https://pubmed.ncbi.nlm.nih.gov/37076309/

 

Copyright 2024 | IGOS | Disclaimer | website: Bitfactory | Financially supported by the GBS-CIDP Foundation International.